- Speedy dispute resolution on Indian IPR policy agenda
- US keeps India on IPR watch list but expectations run high
- Peeved Bayer to USTR: Indian govt picking winners
- India's public sector pharma: flogging a dead horse?
ANALYSIS Other Informa Analysis
- The EMA at 20: Guido Rasi looks at how the EU regulatory landscape might change over the next decade
- INTERVIEW: Clinuvel's Philippe Wolgen on Scenesse and the patient factor
JOB OF THE WEEK Promote your job vacancy